Search

Home > New FDA Approvals > 017 - Janssen’s golimumab (Simponi Aria) for psoriatic arthritis and ankylosing spondylitis; FDA to address teen E-cigarette use in public education campaign; Synlogic’s oral drug SYNB1618 for PKU granted orphan drug status; FDA’s draft guidance upd
Podcast: New FDA Approvals
Episode:

017 - Janssen’s golimumab (Simponi Aria) for psoriatic arthritis and ankylosing spondylitis; FDA to address teen E-cigarette use in public education campaign; Synlogic’s oral drug SYNB1618 for PKU granted orphan drug status; FDA’s draft guidance upd
Category: Science & Medicine
Duration: 0
Publish Date: 2017-10-25 05:30:55
Description:

October 25, 2017

0:30 FDA approves Janssen’s golimumab (Simponi Aria) for psoriatic arthritis and ankylosing spondylitis 

http://bit.ly/2yJmi2h

1:40 FDA to address teen E-cigarette use in public education campaign

https://csnews.com/fda-address-teen-e-cigarette-use-public-education-campaign

https://csnews.com/drop-e-cig-use-drives-decline-youth-tobacco-use 

4:30 Synlogic’s oral drug SYNB1618 for phenylketoneuria granted orphan drug status

5.44 FDA’s draft guidance updates breakthrough devices program to speed access to new devices

http://raps.org/Regulatory-Focus/News/2017/10/24/28738/Breakthrough-Devices-FDA-Issues-Draft-Guidance/

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581861.htm

 If we can assist with any medical writing, please email us at info@nascentmc.com
Total Play: 0